Hoba Therapeutics was established November 2016 and funded by Novo Seeds and Borean Innovation. The company is developing biopharmaceuticals for the treatment of pain and CNS disorders. Our pipeline includes two patented endogenous neurotrophic factors with shared properties. The lead compound is HB-086 (human recombinant Meteorin) and preclinical studies support therapeutic use in neuropathy and associated neuropathic pain. HB-097 (human recombinant Cometin) is in early preclinical development for hearing disorders. Our mission is to provide innovative effective, safe and disease modifying treatments to patients living with neuropathic pain.